Market Place
Sourcing Support
Lexicon Presents Sotagliflozin Data at AHA 2024 in Chicago
14 Nov 2024 //
GLOBENEWSWIRE
Sotagliflozin Efficacy & Safety for Type 1 Diabetes at ASNKD
05 Nov 2024 //
GLOBENEWSWIRE
Lexicon Reports FDA Advisory Committee Outcome for Zynquista™
31 Oct 2024 //
GLOBENEWSWIRE
Viatris Announces Licenses Sotagliflozin Outside U.S. And Europe
16 Oct 2024 //
PR NEWSWIRE
Lexicon Announces Licensing Agreement With Viatris For Sotagliflozin
16 Oct 2024 //
GLOBENEWSWIRE
Viatris lays out $25M to tackle marketing of Lexicon`s Inpefa
15 Oct 2024 //
FIERCE PHARMA
Lexicon To Present Phase 3 Trial Design For Sotagliflozin In HCM
27 Sep 2024 //
GLOBENEWSWIRE
nVNS Effective In Accelerating Air Force Pilot Training
10 Sep 2024 //
GLOBENEWSWIRE
Analysis Shows INPEFA Benefits Heart Failure Patients Irrespective of Diabetes
03 Sep 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
21 Aug 2024 //
GLOBENEWSWIRE
Lexicon Pharma Announces Strategic Repositioning For Growth
13 Aug 2024 //
GLOBENEWSWIRE
Lexicon Presents Sotagliflozin Data At Diabetes Care Specialists Conference
07 Aug 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals Reports Q2 2024 Results And Business Update
01 Aug 2024 //
GLOBENEWSWIRE
Lexicon Gets Dec 20 PDUFA Date For Sotagliflozin T1D NDA Resubmission
16 Jul 2024 //
GLOBENEWSWIRE
New Data Shows Potential Cost-Savings Of INPEFA For Heart Failure
15 Jul 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
21 Jun 2024 //
GLOBENEWSWIRE
INPEFA® (Sotagliflozin) Cost-Effectiveness Analysis Published In JACC
18 Jun 2024 //
GLOBENEWSWIRE
INPEFA Reduced Heart Failure Risk In Preserved EF, Pooled Analysis Shows
14 May 2024 //
GLOBENEWSWIRE
Lexicon Pharma Q1 2024 Results, Business Update
02 May 2024 //
GLOBENEWSWIRE
Clinical Data on Impact of Sotagliflozin on StrokeHeart Attack Risk Four Lexicon
25 Mar 2024 //
GLOBENEWSWIRE
Lexicon preps FDA resubmission for diabetes hopeful Zynquista
12 Mar 2024 //
FIERCE PHARMA
INPEFA Use Associated With Early Clinical Benefit in Heart Failure
12 Nov 2023 //
GLOBENEWSWIRE
Data on Benefit for INPEFA Will Be Among Five Lexicon-Sponsored Presentations
02 Nov 2023 //
GLOBENEWSWIRE
INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts
01 Nov 2023 //
GLOBENEWSWIRE
New Data Relating to Sotagliflozin to be Presented at ASN Kidney Week 2023
30 Oct 2023 //
GLOBENEWSWIRE
Data From Studies Demonstrating Financial Impact of INPEFA to be Presented
17 Oct 2023 //
GLOBENEWSWIRE
Data Demonstrating Financial Impact of INPEFA® (Sotagliflozin) to be Presented
11 Oct 2023 //
GLOBENEWSWIRE
INPEFA® (Sotagliflozin) Receives Preferred Formulary Status
09 Oct 2023 //
GLOBENEWSWIRE
Lexicon to Present Post Hoc Analysis of Scored Clinical Trial
28 Sep 2023 //
GLOBENEWSWIRE
Lexicon to Present Study Results Relating to Sotagliflozin and LX9211
26 Sep 2023 //
GLOBENEWSWIRE
Lexicon to Present Analyses of INPEFA Clinical Study Results
21 Aug 2023 //
GLOBENEWSWIRE
Published Analysis of Sotagliflozin Data Shows Reductions in Heart Failure
08 Aug 2023 //
GLOBENEWSWIRE
Lexicon to Present Study Results Relating to LX9211 and INPEFA
20 Jun 2023 //
GLOBENEWSWIRE
Brand Institute Partners with Lexicon on the Brand Name Development for INPEFA
06 Jun 2023 //
PR NEWSWIRE
SGLT latecomer Lexicon gets heart failure okay
29 May 2023 //
PHARMAPHORUM
US FDA approves Lexicon Pharma`s drug for heart failure
27 May 2023 //
HEALTH ET
FDA approves Lexicon’s heart-failure drug after defeat in diabetes
26 May 2023 //
ENDPTS
New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment
10 May 2023 //
GLOBENEWSWIRE
Analyses of Sotagliflozin Showing Time to Benefit Presented at World Congress
04 Mar 2023 //
GLOBENEWSWIRE
Analyses of Sotagliflozin to Be Presented at the American College of Cardiology
20 Feb 2023 //
GLOBENEWSWIRE
In pursuit of approval, Lexicon undaunted against unwavering FDA
01 Dec 2022 //
FIERCEPHARMA
Lexicon slams FDA over hearing denial following CRL for SGLT2 candidate
01 Dec 2022 //
ENDPTS
New Analysis of SOLOIST-WHF Results Sotagliflozin’s Significant Effect
06 Nov 2022 //
GLOBENEWSWIRE
Analyses of Sotagliflozin From SOLOIST-WHF and SCORED Trials to be Presented
31 Oct 2022 //
GLOBENEWSWIRE
SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Heart Failure
02 Oct 2022 //
GLOBENEWSWIRE
Lexicon Highlights Publications Relating to Sotagliflozin`s Mechanism of Action
22 Aug 2022 //
GLOBENEWSWIRE
FDA Accepts Lexicon`s NDA for Sotagliflozin to Treat Heart Failure
27 Jul 2022 //
GLOBENEWSWIRE
FDA again spells out safety concerns with Lexicon`s oral T1D drug
14 Jul 2022 //
ENDPTS
Lexicon refiles for FDA approval of sotagliflozin to treat heart failure
01 Jun 2022 //
SEEKING ALPHA
Sotagliflozin Improved Outcomes in Patients With and Without Prior CVS Disease
04 Apr 2022 //
GLOBENEWSWIRE
Lexicon pulls FDA submission for sotagliflozin to fix issue
01 Mar 2022 //
BENZINGA
Lexicon seeks FDA Approval for NDA of Sotagliflozin in Heart Failure with T2D
01 Jan 2022 //
TRIALSITENEWS
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment
30 Dec 2021 //
GLOBENEWSWIRE
Lexicon’s Sotagliflozin Demonstrates Benefits in Heart Failure and Blood Glucose
13 Nov 2021 //
GLOBENEWSWIRE
Lexicon’s Sotagliflozin Shows Additional Benefits in Reducing CVS Endpoints
23 Aug 2021 //
GLOBENEWSWIRE
Early Use Of Sotagliflozin Provides Benefits T2DM Patients With comorbidities
29 Jun 2021 //
PRNEWSWIRE
DEPARTMENT OF HEALTH AND HUMAN SERVICES
02 Mar 2021 //
FEDERALREGISTER
LEXICON PROVIDES REGULATORY UPDATE ON SOTAGLIFLOZIN IN HEART FAILURE
14 Jan 2021 //
PRESS RELEASE
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
18 Nov 2020 //
NEJM
Results From SOLOIST & SCORED Outcomes Studies Presented at Late-Breaking Scienc
17 Nov 2020 //
GLOBENEWSWIRE
